Actuate Therapeutics Inc
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). Its core product is elraglusib, a novel GSK-3β inhibitor designed to block molecular pathways involved in tumor growth and resistance to conventional cancer treatments. Elraglusib is being developed in multiple formulations, including an intravenous injection (Actuate-1801) for metastatic pancreatic ductal adenocarcinoma (mPDAC) and oral tablet forms aimed at expanding treatment indications and improving dose convenience. The company’s pipeline also includes clinical trials in refractory pediatric malignancies such as Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. Actuate Therapeutics operates primarily in the United States and focuses on oncology markets with a high unmet medical need. Founded in 2015 and headquartered in Fort Worth, Texas, Actuate has licensed its GSK-3 inhibitor portfolio from the University of Illinois-Chicago and Northwestern University. In the last 1-2 years, Actuate Therapeutics has made several major strategic advances including completing a $17.25 million public offering of common stock in 2025 and entering into a $100 million at-the-market issuance sales agreement to finance ongoing operations. The company has also provided the FDA with updated clinical data supporting regulatory interactions for elraglusib’s use as first-line treatment for metastatic pancreatic cancer, reporting significant positive Phase 2 trial outcomes such as a 37% reduction in risk of death and doubled 12-month survival rate when combined with standard chemotherapy. Actuate has entered a collaboration with Incyte Corporation and the University of Pittsburgh to study elraglusib in combination therapies for advanced pancreatic cancer. It is actively developing its oral tablet formulation with plans for a Phase 1 dose-finding study, subject to funding. The company continues to invest heavily in research and development as it seeks regulatory approvals and commercial opportunities in oncology therapeutics while maintaining a focus on innovative treatment options for hard-to-treat cancers.
Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
Analysts see 200%+ upside in these 3 high-risk stocks: here's why?
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
Actuate Therapeutics drug improves survival odds in pancreatic cancer trial
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers
Gossamer Bio (NASDAQ:GOSS) versus Actuate Therapeutics (NASDAQ:ACTU) Critical Survey
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
Todd Thomson Sells 280,000 Shares of Actuate Therapeutics (NASDAQ:ACTU) Stock
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock?
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06%
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock